{"id":2422,"date":"2019-10-06T01:29:23","date_gmt":"2019-10-05T23:29:23","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2422"},"modified":"2024-03-12T10:56:54","modified_gmt":"2024-03-12T09:56:54","slug":"breast-cancer","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/breast-cancer\/","title":{"rendered":"Breast cancer"},"content":{"rendered":"\n
The Breast Cancer research group aims to better understand breast cancer development, the origin of disease subtypes, and disease progression and vulnerabilities. The research projects comprise the major disease subtypes as well as BRCA1\/2-mutant breast cancer. The group also works to develop novel targeted preventive approaches and to improve the quality of life of patients. This is a multidisciplinary team that combines the experience and knowledge of clinical and translational researchers.<\/p>\n
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer<\/strong>. N. Engl. J. Med. 2022;387(1):9-20. doi:10.1056\/NEJMoa2203690.<\/p>\n Langille E, Al Zahrani KN, Ma Z, Liang M, Uuskula Reimand L, Espin R, Teng K, Malik A, Bergholtz H, El Ghamrasni S, Afiuni Zadeh S, Tsai R, Alvi S, Elia A, Lu Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD, Egan SE, Cescon DW, Sorlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK, Knudsen ES, Pujana MA, Wahl GM, Schramek D. Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis and promotes breast cancer<\/strong>. Cancer Discov. 2022;doi:10.1158\/2159-8290.CD-21-0865.<\/p>\n Mateo F, He Z, Mei L, de Garibay GR, Herranz C, Garc\u00eda N, Lorentzian A, Baiges A, Blommaert E, G\u00f3mez A, Mirallas O, Garrido Utrilla A, Palomero L, Esp\u00edn R, Extremera AI, Soler Mons\u00f3 MT, Petit A, Li R, Brunet J, Chen K, Tan S, Eaves CJ, McCloskey C, Hakem R, Khokha R, Lange PF, L\u00e1zaro C, Maxwell CA, Pujana MA. Modification of BRCA1-associated breast cancer risk by HMMR overexpression<\/strong>. Nat. Commun. 2022;13(1):1895-1895. doi:10.1038\/s41467-022-29335-z.<\/p>\n He Z, Ghorayeb R, Tan S, Chen K, Lorentzian AC, Bottyan J, Aalam SMM, Pujana MA, Lange PF, Kannan N, Eaves CJ, Maxwell CA. Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation<\/strong>. Nat. Commun. 2022;13(1):2200-2200. doi:10.1038\/s41467-022-29885-2.<\/p>\n Guix I, Liu Q, Pujana MA, Ha P, Piulats J, Linares I, Guedea F, Mao JH, Lazar A, Chapman J, Yom SS, Ashworth A, Barcellos Hoff MH. Validation of anti-correlated TGF\u00df signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy<\/strong>. Clin. Cancer Res. 2022;28(7):1372-1382. doi:10.1158\/1078-0432.CCR-21-2846.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t LCX21020. Becas de posdoctorado Junior Leader Incoming<\/strong>. FUNDACI\u00d3 “LA CAIXA”. Budget: 297900. 2022-2025. PI: Pujana PUJANA, Miguel \u00c1ngel.<\/p>\n 19FIS022. Atlas de moduladores moleculares del c\u00e1ncer y validaci\u00f3n en el subtipo receptor estr\u00f3genopositivo de c\u00e1ncer de mama<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 233832,5. 2019-2022. PI: Pujana PUJANA, Miguel \u00c1ngel.<\/p>\n FIS21092. BASE BIOL\u00d3GICA DE LA MODIFICACI\u00d3N DEL RIESGO DE C\u00c1NCER DE MAMA: HACIA LA MEJORA DE LA PREVENCI\u00d3N<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 196020. 2022-2024. PI: Pujana PUJANA, Miguel \u00c1ngel.<\/p>\n 20ACL092. ESTUDIO DE FASE III, MULTIC\u00c9NTRICO, ALEATORIZADO (1:1), DOBLE CIEGO, CONTROLADO CON PLACEBO, DE DOS PARTES PARA EVALUAR LA EFICACIA Y SEGURIDAD DE ALPELISIB (BYL719) EN COMBINACI\u00d3N CON TRASTUZUMAB Y PERTUZUMAB COMO TERAPIA DE MANTENIMIENTO EN PACIENTES CON C\u00c1NCER DE MAMA AVANZADO HER2 POSITIVO CON UNA MUTACI\u00d3N DE PIK3CA<\/strong>. Novartis Farmac\u00e9utica, S.A.. Budget: 152413,02. 2020- . PI: Pernas Sim\u00f3n, Sonia.<\/p>\n 21ACL065. TENACIDAD:<\/strong> UN ESTUDIO DE FASE 2, MULTIC\u00c9NTRICO, ABIERTO, DE BRAZO \u00daNICO SOBRE LA MONOTERAPIA DE AL101 EN PACIENTES CON C\u00c1NCER DE MAMA TRIPLE NEGATIVO CON ACTIVACI\u00d3N DE NOTCH<\/strong>. PRECISION FOR MEDICINE, LLC. Budget: 123322,3. 2021- . PI: Pernas Sim\u00f3n, Sonia.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT077-“Dna Damage Repair Deficit In Cancer Cells” The group has extensive experience in bioinformatic and systems biology approaches, combined with in vitro and in vivo experimental studies, aimed at better understanding the development and progression of breast cancer. Over the past five years, the team has published 50 articles on a regular basis, including various manuscripts in leading journals. The team has also received various national and international grants and has established strong collaborations with national and international leaders in the area.<\/p>\n\t\t\t\t\n Breast cancer Summary The Breast Cancer research group aims to better understand breast cancer development, the origin of disease subtypes, and disease progression and vulnerabilities. The research projects comprise the major disease subtypes as well as BRCA1\/2-mutant breast cancer. The group also works to develop novel targeted preventive approaches and to improve the quality of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-05 16:48:47","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2422"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2422"}],"version-history":[{"count":6,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2422\/revisions"}],"predecessor-version":[{"id":23764,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2422\/revisions\/23764"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Miguel Angel Pujana
\nOWNERSHIP: 25%IDIBELL-ICO, 75% UNIVERSITY OF CALIFORNIA (UCSF)
\nREQUEST No.: US63\/038,747
\nPRIORITY COUNTRY: USA
\nPRIORITY DATE: 12\/06\/2020
\nPCT APPLICATION: WO2021\/252945 (11\/06\/2021)\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\n\t\tGenestar Pujana, Miguel Angel\n\t<\/h4>\n
\n\t\t\n\t\tmgenestar@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\n
\n\t\tGenestar Pujana, Miguel Angel\n\t<\/h4>\n
\n\t\t\n\t\tmgenestar@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tGarc\u00eda Tejedor, Amparo\n\t<\/h4>\n
\n\t\t\n\t\tagarciat@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tObadia Gil, Veronica Luisa\n\t<\/h4>\n\t\t\t\t\n
\n\t\tFernandez Ortega, Adela\n\t<\/h4>\n
\n\t\t\n\t\tafernandezo@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tPla Farn\u00f3s, Mar\u00eda Jes\u00fas\n\t<\/h4>\n\t\t\t\t\n
\n\t\tPernas Simon, Sonia\n\t<\/h4>\n
\n\t\t\n\t\tspernas@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tFalo Zamora, Catalina\n\t<\/h4>\n
\n\t\t\n\t\tcfalo@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tGil Gil, Juan Miguel\n\t<\/h4>\n
\n\t\t\n\t\tjmgil@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tAntolin Hernandez, Albert\n\t<\/h4>\n
\n\t\t\n\t\taantolin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tRELATED LINKS\n\t<\/h4>\n
\n\t\t\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@ProcureICO\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@PujanaLab\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@SoniaPernas\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@AmpaGarTej\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tCIMBA\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders \t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators \t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers \t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders \n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAn anticancer drug opens a new path for the treatment of Parkinson’s<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/02\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAlterations in the blood immune system found to increase cancer risk<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t06\/02\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tScientists open up a new way to fight cancer through the MYC gene<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t19\/12\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAELAM donates 15.000\u20ac to research on Lymphangioleiomyomatosis<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/11\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tThe DACMA Association donates 10,000 euros for breast cancer research<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t16\/03\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL organized a meeting of breast cancer solidarity donors and associations<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/09\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA new treatment is effective for advanced HER2-low breast cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t05\/06\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tResearchers identify the biological basis responsible for developing breast cancer in patients with mutations in BRCA1<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t07\/04\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tMolecular screening in advanced breast cancer patients allows for personalized therapeutic decisions<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t13\/01\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tWe close a 2021 full of science!<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"